Credit Suisse Group set a $100.00 price target on Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Thursday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
Other analysts also recently issued reports about the stock. BidaskClub raised shares of Sarepta Therapeutics from a buy rating to a strong-buy rating in a research report on Thursday, March 15th. Zacks Investment Research downgraded shares of Sarepta Therapeutics from a hold rating to a sell rating in a research report on Friday, January 5th. Royal Bank of Canada reissued a buy rating and issued a $91.00 target price on shares of Sarepta Therapeutics in a research report on Wednesday, March 14th. UBS reissued an outperform rating and issued a $56.51 target price (down from $76.00) on shares of Sarepta Therapeutics in a research report on Wednesday, December 27th. Finally, HC Wainwright set a $75.00 target price on shares of Sarepta Therapeutics and gave the stock a buy rating in a research report on Monday, February 12th. Four equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. Sarepta Therapeutics presently has a consensus rating of Buy and a consensus target price of $78.87.
SRPT stock opened at $71.74 on Thursday. The company has a current ratio of 13.91, a quick ratio of 12.96 and a debt-to-equity ratio of 0.54. Sarepta Therapeutics has a 12 month low of $28.14 and a 12 month high of $84.37.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.05). The business had revenue of $57.30 million during the quarter, compared to the consensus estimate of $57.33 million. Sarepta Therapeutics had a negative return on equity of 30.59% and a negative net margin of 32.79%. The business’s revenue was up 961.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.71) earnings per share. analysts anticipate that Sarepta Therapeutics will post -1.18 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in Sarepta Therapeutics by 0.9% during the 4th quarter. BlackRock Inc. now owns 6,286,343 shares of the biotechnology company’s stock valued at $349,773,000 after purchasing an additional 58,433 shares during the last quarter. Fred Alger Management Inc. raised its stake in Sarepta Therapeutics by 10.5% during the 4th quarter. Fred Alger Management Inc. now owns 1,581,525 shares of the biotechnology company’s stock valued at $87,996,000 after purchasing an additional 149,712 shares during the last quarter. Jennison Associates LLC raised its stake in Sarepta Therapeutics by 0.6% during the 4th quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock valued at $63,998,000 after purchasing an additional 6,357 shares during the last quarter. Gilder Gagnon Howe & Co. LLC raised its stake in Sarepta Therapeutics by 63.4% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 872,824 shares of the biotechnology company’s stock valued at $48,564,000 after purchasing an additional 338,737 shares during the last quarter. Finally, Carillon Tower Advisers Inc. acquired a new position in Sarepta Therapeutics during the 4th quarter valued at $38,720,000. Hedge funds and other institutional investors own 84.98% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/04/08/credit-suisse-group-analysts-give-sarepta-therapeutics-srpt-a-100-00-price-target.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.